Showing 1 posts of 31 posts found.
US pharmaceutical company Hospira has acquired worldwide rights to a biogeneric version of Amgen's neutropenia treatment Neupogen (filgrastim) in a …
NHS England approves delayed-release treatment for rare kidney disease
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease
Data integrity: the keystone for AI adoption, patient safety and organisational reputation